3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Nasopharyngeal Carcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Melanoma
2
Carcinoma, Non-Small-Cell Lung
2
Recurrence
1
Oligoprogressive
1
Neoplasms
1
Neoplasm Metastasis
1
NSCLC
1
Meningeal Carcinomatosis
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Advanced Solid Tumors
1
Interventions
pembrolizumab
30
Paclitaxel
12
Carboplatin
10
Cisplatin
8
lenvatinib
7
Pemetrexed
5
belzutifan
4
Oxaliplatin
4
Gemcitabine
4
Fluorouracil
4
Capecitabine
4
patritumab deruxtecan
3
olaparib
3
Leucovorin
3
Albumin-Bound Paclitaxel
3
Acetaminophen
3
Levoleucovorin
2
Irinotecan
2
Histamine H2 Antagonists
2
Histamine Antagonists
2
Etoposide
2
Docetaxel
2
Dexamethasone
2
Cetuximab
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Immune Checkpoint Inhibitors
×
30 days
×
Clear all
No trials found.